#RareDiseaseDay2025

by | Feb 28, 2025 | GBM, LM, PBC, Uncategorized

Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...

ReSPECT-LM Phase 1 Single Dose Completed

by | Feb 26, 2025 | LM

BREAKING NEWS: ReSPECT-LM Phase 1 Single Dose Completed – Phase 2 Dose Determined We are thrilled to announce a major milestone in the ReSPECT-LM clinical trial! The Phase 1 single-dose portion of the trial is now complete, and the recommended Phase 2 dose (RP2D) for...

CNSide Diagnostics Leadership Appointments

by | Feb 25, 2025 | LM

Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...

Welcome Michael Rosol, PhD!

by | Feb 20, 2025 | GBM, LM, PBC, Uncategorized

Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...

$5.7 Million PSTV Funding

by | Feb 18, 2025 | GBM, LM, PBC, Uncategorized

Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...